@entity5305 for XXXX .

@entity1 @entity410 @entity5305 @entity739 @entity2473
We reviewed 20 @entity1 receiving @entity5305 for @entity739 . @entity1 were not enrolled in a formal study. All families obtained the medication abroad. Age at initiation of @entity5305 ranged from 1 to 48 months; nine @entity1 had received prior treatment with various antiepileptic medications. @entity1 were begun on the lowest practical dose of 125-250 mg/day, with gradual daily increments to a target of 100 mg/kg/day, but maintained at the lowest effective dosage. Video electroencephalogram was obtained to document resolution of @entity2473 and @entity739 . Of 20 @entity1 , 12 responded with cessation of @entity2473 and resolution of @entity739 , at doses of 25-135 mg/kg/day (median = 58 mg/kg/day). Partial responses were observed in six @entity1 , whereas two had no response at 111 and 125 mg/kg/day. Additional new @entity410 types developed in three @entity1 after initial response to @entity5305 . Increasing the @entity5305 did not have any clinical benefit. @entity5305 is an effective, well-tolerated treatment for @entity739 . The response is dose-independent, suggesting that starting at a low dose and gradually increasing, rather than beginning with an arbitrary 100 mg/kg/day dose is advantageous.
